COMPANY PROFILE

SBK Biomedical

Explore full profile

Pioneering anti-cancer drugs in China with a focus on cardiovascular and respiratory diseases

ChinaFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2025

Total funding $10–50M Disclosed equity funding

Unlock exact values

About SBK Biomedical

Shebacon is a pharmaceutical company dedicated to the research and development of new drugs, particularly in the field of anti-cancer medications. The company operates within the Chinese market, aiming to address the historical challenges faced by Chinese anti-cancer drugs in gaining acceptance. By focusing on diseases affecting the cardiovascular and respiratory systems, Shebacon has advanced several products to the clinical trial phase. The business model revolves around sustaining corporate innovation through a four-way drive, positioning itself as a leader in global drug differentiation. Revenue is generated through the development and eventual commercialization of these specialized medications. Shebacon's recognition as a Growing Enterprise for Urban Small and Medium Sized Enterprises in both 2022 and 2023 underscores its commitment to growth and innovation in the pharmaceutical sector.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: China
Open positions: None listed
Dealroom signal: 21.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Cardiology and cardiovascular, Respiratory, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Aug 2025	$14M	$55M	Chengda Pharmaceutical	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

SBK Biomedical website traffic

Latest recorded traffic for SBK Biomedical is 140 monthly website visits.

Latest monthly visits140

Monthly website visitsApr 2026–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NPNovo PathDeveloped an extracorporeal device to effectively and specifically extract plasma proteins responsible for hyperfibrinolysis	Nazareth, Israel	Operational	60	$2.3M	—
COCelyad OncologyIntellectual property licensing for CAR T-cell therapies	Mont-Saint-Guibert, Belgium	Operational
RPReata PharmaceuticalsBiopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases	Plano, United States	Acquired
HBHawkeye BioA new preventive screening paradigm for lung cancer	Torrance, United States	Operational
BGBanook GroupComprehensive clinical trial solutions with a focus on cardiac safety, endpoint adjudication, and central imaging	Nancy, France	Acquired
GSGene Techno ScienceGene Techno Science is engaged in the research and development of biopharmaceutical products and biosimilars in Japan	Sapporo, Japan	Acquired
ZTZensun (Shanghai) Sci & TechA biopharmaceutical company focusing on the development of innovative bio-therapeutic	Huangpu, China	Operational
CECervoMedSmall molecule therapeutics for treating life-threatening medical conditions	Charlottesville, United States	Operational